ALKS 5461 is an investigational opioid system modulator for adjunctive treatment of major depressive disorder (MDD) comprised of buprenorphine (BUP) and samidorphan (SAM), a μ-opioid receptor antagonist added to address the abuse/dependence potential of BUP. The ability of SAM to address the abuse potential of BUP in the ALKS 5461 combination was explored.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Biological Psychiatry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2018 Published by Elsevier Inc.